



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – New Programs: Fludarabine, Cyclophosphamide and Rituximab in CLL (LYFCR), 3-Day Etoposide, Ifosfamide with Mesna in Advanced Soft Tissue or Bony Sarcoma (SAAVIME3)
- **Provincial Systemic Therapy Program** – Chinese and Punjabi Translated Protocol Patient Handouts
- **Cancer Drug Manual** – New: Lambrolizumab (Interim); Revised: Etoposide, Pazopanib, Temozolomide; Change in Terminology to Non-DEHP from Non-PVC: Cabazitaxel, Docetaxel, Etoposide, Ixabepilone, Paclitaxel, Temsirolimus, Teniposide
- **Benefit Drug List** – New: LYFCR, SAAVIME3
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: UHNNVAVCAP, LYFCR, SAAVIME3; Revised: BRAJACTG, BRAJACTT, UBRAJDAC, BRAVTR, CNAJTZRT, CNTEMOZ, CNTEMOZMD, GICAPIRI, GIENDO2, GIFOLFIRI, UGIPNEVER, GOBEP, GOCXCRT, GOOVVIN, UGUAXIT, GUBPWRT, HLHETCSPA, ULKATOATRA, ULKATOP, ULUAVCRIZ; New Translated Protocol Patient Handouts (Chinese & Punjabi): GIEFUPRT, GIFUART, GIFUPART, GIGAIRT, GIRCRT
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following programs effective 01 July 2014:

Lymphoma:

Fludarabine, Cyclophosphamide and Rituximab for Chronic Lymphocytic Leukemia (CLL) (LYFCR) – The BCCA Lymphoma Tumour Group has introduced this new treatment program for CLL patients with high-risk disease (e.g. deletion in chromosome 11 [11q deletion]) who are young and fit. Currently, the treatment standard for CLL in British Columbia is fludarabine and rituximab (LYFLUDR). This regimen balances efficacy with tolerability in most CLL patients, whose median age of diagnosis is 72 years and many of whom may have comorbidities. Phase III data have shown that in patients who are young and fit, the combination of fludarabine, cyclophosphamide and rituximab is associated with a higher response rate compared to fludarabine and cyclophosphamide alone (65% vs. 45%). [Hallek et al. Lancet 2010;376:1164–74] In addition, emerging data show that the LYFCR regimen is associated with prolonged progression free survival (median 58 months) and overall survival (70% at 6 years) in patients with high-risk disease. [Fischer K et al. IWCLL 2013].

Sarcoma:

3-Day Regimen of Etoposide and Ifosfamide with Mesna for Advanced Soft Tissue or Bony Sarcoma

EDITOR'S CHOICE

(SAAVIME3) – The BCCA treatment standard for advanced soft tissue or bony sarcoma is a 5-day regimen of etoposide and ifosfamide with mesna (SAIME). A modified 3-day regimen (SAAVIME3) has been created, and has been used successfully in the palliative setting with good patient satisfaction. The 3-day regimen may be more suited for patients with advanced incurable disease.

PROVINCIAL SYSTEMIC THERAPY PROGRAM

TRANSLATION OF PROTOCOL PATIENT HANDOUTS

Chinese and Punjabi translations are now available for a number of Protocol Patient Handouts (see affected handouts in the table [below](#)). This is part of an ongoing BCCA pilot project to address the needs of non-English speaking patients throughout the province. According to the 2006 Census, 12.4% of the BC population reported Chinese (8.5%) or Punjabi (3.9%) as their native language; approximately one in five of these individuals have no working knowledge of English.

CANCER DRUG MANUAL

NEW MONOGRAPHS AND PATIENT HANDOUTS

Lambrolizumab (Pembrolizumab) Interim Monograph has been completed. It is an intravenously administered humanized monoclonal antibody currently being investigated for advanced melanoma. It targets the programmed cell death 1 (PD-1) receptors, preventing the binding of associated ligands (PD-L1 and PD-L2) to the receptors. Common adverse reactions reported include fatigue, rash, pruritis and diarrhea. Lambrolizumab is not a benefit drug of the BCCA, and is currently available in Canada only through the Health Canada Special Access Programme.

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Etoposide Monograph:

- *Interactions table* – corrected typo in grapefruit interaction

Pazopanib Monograph and Handout:

- *Pharmacokinetics table* – updated to include new product information about pH-dependent solubility
- *Interactions table* – added esomeprazole interaction
- *Handout* – updated interactions information

Temozolomide Monograph and Handouts:

- *Caution and Side Effects sections* – updated to include potentially fatal hepatic toxicity
- *Handouts (IV and oral)* – added signs of liver problems to “See your doctor” section

CANCER DRUG MANUAL

CHANGE IN TERMINOLOGY TO NON-DEHP FROM NON-PVC

Di(2-ethylhexyl) phthalate (DEHP) is a chemical additive that is used to make polyvinyl chloride (PVC) in medical devices (e.g. intravenous tubings and bags) soft, flexible and kink-resistant. However, because certain drug solutions are capable of extracting DEHP from PVC containers, these drugs must be prepared and administered in devices which do not contain DEHP. The terms “non-PVC” and “non-DEHP” were once used interchangeably, but are now known to be different. As such, the terms “non-DEHP” has replaced “non-PVC” in the following CDM monographs and in the Chemotherapy Preparation and Stability Chart. This information will also be updated in the affected BCCA protocols and PPPOs soon.

- Cabazitaxel
- Docetaxel
- Etoposide
- Ixabepilone
- Paclitaxel
- Temsirolimus
- Teniposide

BENEFIT DRUG LIST

NEW PROGRAMS

The following programs have been added to the [Benefit Drug List](#) effective 01 July 2014:

Protocol Title	Protocol Code	Benefit Status
Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and riTUXimab	LYFCR	Class II
3-Day Etoposide & Ifosfamide-Mesna for Patients with Advanced Soft Tissue or Bony Sarcomas	SAAVIME3	Class I

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UHNNAVCAP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment Of Recurrent Or Metastatic Nasopharyngeal Cancer With Capecitabine
LYFCR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and riTUXimab

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
SAAVIME3	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	3-Day Etoposide & Ifosfamide-Mesna for Patients with Advanced Soft Tissue or Bony Sarcomas

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJACTG	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Reformatted, minor typo corrected</i>	Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide followed by PACLitaxel
BRAJACTT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of lab tests clarified</i>	Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab
UBRAJDAC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of lab tests clarified</i>	Adjuvant Therapy for Breast Cancer using Cyclophosphamide, DOXOrubicin and DOCEtaxel
BRAVTR	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Reformatted, minor typo corrected</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab
CNAJZRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Liver function tests clarified</i>	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation
CNTEMOZ	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Liver function tests clarified</i>	Therapy for Malignant Brain Tumours using Temozolomide
CNTEMOZMD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Liver function tests clarified</i>	Therapy for Malignant Brain Tumours Using Metronomic Dosing of Temozolomide
GICAPIRI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Protocol Title updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuitable for GIFOLFIRI
GIENDO2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and Doxorubicin
GIFOLFIRI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol Title updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Leucovorin
UGIPNEVER	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using Everolimus
GOBEP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Lung function tests clarified</i>	Therapy of Non-Dysgerminomatous Ovarian Germ Cell Cancer Using Bleomycin, Etoposide, and CISplatin

REVISED PROTOCOLS, PPPOS AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GOCXCRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Booking information clarified</i>	Treatment of High Risk Squamous Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma of the Cervix with Concurrent CISplatin and Radiation
GOOVIN	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Vinorelbine
UGUAXIT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Therapy for Metastatic Renal Cell Carcinoma Using Axitinib
GUBPWRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Magnesium infusion time updated</i>	Treatment of Locally Advanced Bladder Cancer with Weekly CISplatin and Concurrent Radiation
HLHETCSPA	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Etoposide volume, cotrimoxazole and fluconazole dosing clarified</i>	Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and cycloSPORINE
ULKATOATRA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Baseline tests and treatment duration clarified</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)
ULKATOP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Induction regimen added, baseline tests and treatment duration clarified; Protocol Title updated</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and Daunorubicin
ULUAVCRIZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications added</i>	Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib

NEW TRANSLATED PROTOCOL PATIENT HANDOUTS (CHINESE AND PUNJABI):

CODE	Protocol Title
GIEFUPRT	Therapy for Locally Advanced Esophageal cancer using Combined Cisplatin, Infusional Fluorouracil and Radiation therapy
GIFUART	Curative-Intent Combined Treatment for Cancer of the Anal Canal using Mitomycin, Infusional Fluorouracil and Radiation Therapy
GIFUPART	Curative-Intent Combined Treatment for Cancer of the Anal Canal using Cisplatin, Infusional Fluorouracil and Radiation Therapy
GIGAIRT	Combined Modality Adjuvant Therapy For Completely Resected Stomach Cancer Using Fluorouracil And Folinic Acid (Leucovorin) And Radiation Therapy
GIRCRT	Adjuvant Therapy for High Risk Cancer of the Rectum with Combined Capecitabine and Radiation Therapy

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	http://www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 673028		sally.waignein@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN
 Rob Watt, BSc (Pharm)